Tirzepatide 20mg / 40mg
Metabolic
Overview
Tirzepatide is a 39-amino-acid dual agonist that binds both the GIP and GLP-1 receptors from a single peptide backbone, with a C20 fatty-diacid moiety that extends its half-life in solution. Supplied as a sterile lyophilised powder in 20mg and 40mg vials, verified to ≥98% purity by RP-HPLC and confirmed by mass spectrometry.
Classification: Tirzepatide (LY3298176) — a synthetic 39 amino-acid dual-agonist peptide with a C20 fatty-diacid moiety, based on the native GIP sequence with modifications enabling GLP-1 receptor activity.
Research background
In vitro, Tirzepatide is used to characterise co-activation of the GIP and GLP-1 receptors — including cAMP accumulation, β-arrestin recruitment and receptor-bias studies. It is often used as a comparator peptide when characterising newer molecules such as Retatrutide or Cagrilintide combinations.
This summary describes published preclinical and, where applicable, clinical research. It is not a medical claim and does not describe or endorse any human use of the compound as sold by Peptides UK 4U.
Mechanism of action (under investigation)
Published research characterises tirzepatide as a dual agonist at the GIP and GLP-1 receptors, with reported biased signalling at the GLP-1 receptor relative to native GLP-1. Preclinical and clinical literature examines the combined incretin signalling profile that distinguishes tirzepatide from single-receptor GLP-1 analogues.
Laboratory handling
Reconstitute with bacteriostatic water in a sterile environment. The C20 fatty-diacid modification gives good stability in solution; prepare working aliquots to minimise repeated freeze-thaw cycles.
Storage & stability
- Lyophilised vials: store below -18°C, protected from light.
- Reconstituted solution: refrigerate at 2–8°C and use within 30 days.
- Avoid repeated freeze-thaw cycles to preserve peptide integrity.
For reconstitution volumes and target working concentrations use our peptide calculator. We do not publish dosing protocols for human use.
Product specifications
- Peptide Type
- Dual receptor agonist (GIP / GLP-1)
- Sequence length
- 39 amino acids
- Molecular weight
- ≈4,813 Da
- Form
- Lyophilised powder
- Quantity
- 20mg or 40mg per vial
- Purity
- ≥98% by RP-HPLC + MS
- Solubility
- Water / bacteriostatic water
- CAS
- 2023788-19-2
Certificate of Analysis: Batch-specific COA available. View COAs.
Frequently asked questions
How is Tirzepatide different from Semaglutide?
Semaglutide is a single-receptor GLP-1 analogue; Tirzepatide activates both the GLP-1 and GIP receptors from one 39-residue peptide, which is the main variable researchers compare in incretin studies.
What is the reported half-life of Tirzepatide?
Published pharmacokinetic data reports a half-life of approximately 5 days (~120 hours), enabled by the C20 fatty-diacid modification that binds albumin. This supports once-weekly administration in research protocols.
What purity is your Tirzepatide?
Every vial is tested to ≥98% purity by RP-HPLC and confirmed by mass spectrometry (~4,813 Da). A batch-specific Certificate of Analysis is published on our COA page.
20mg vs 40mg — is there any difference in the peptide?
No — both vials contain the same peptide at the same purity. The 40mg vial simply gives more working volume per reconstitution and lower cost per mg.
How is Tirzepatide reconstituted?
Reconstitute with bacteriostatic water in a sterile laboratory environment. For target concentrations and volumes, use our peptide calculator.
How long is reconstituted Tirzepatide stable?
Kept refrigerated at 2–8°C and protected from light, reconstituted Tirzepatide remains suitable for in vitro research use for up to ~30 days. Avoid repeated freeze-thaw cycles.
Do you ship Tirzepatide from the UK?
Yes — all Tirzepatide vials are UK-stocked with next-working-day dispatch on orders placed before 2pm.
Do you supply a Certificate of Analysis?
Yes — a third-party HPLC + MS COA is linked from the product page for every batch.
References
- Coskun T et al., Molecular Metabolism 18:3–14 (2018) — LY3298176 discovery
- Frías JP et al., NEJM 385(6):503–515 (2021) — SURPASS-2 study
- Jastreboff AM et al., NEJM 387(3):205–216 (2022) — SURMOUNT-1 study
References are provided for educational context. Citation does not imply endorsement of any specific use.
Disclaimer: This article is provided for laboratory and educational purposes only. It is not medical advice and does not describe or endorse any human use. All products sold by Peptides UK 4U are for laboratory research only, are not for human or veterinary consumption, and are not intended to diagnose, treat, cure or prevent any disease.